Vaginal Swabs Effectively Detect Endometrial Cancer Study Finds

New peer-reviewed research published on April 6, 2026, indicates that molecular signals associated with endometrial cancer can be detected using a simple vaginal swab. The findings, published in the International Journal of Gynecological Cancer, suggest a potential shift toward a less invasive diagnostic pathway for women experiencing symptoms of endometrial cancer.

The research was announced by PinkDx, known as The Gyne Cancer Company™. The study aimed to challenge the long-standing belief in gynecologic oncology that meaningful molecular insights into endometrial cancer require the direct sampling of the uterus.

The Role of Vaginal Swabs in Detection

The study found that vaginal swabs provided a sufficient signal to detect endometrial cancer through the use of RNA-based machine learning. Because of these results, the vaginal swab was selected as the primary sample type for a subsequent study, identified as PNK002, which aims to further develop and validate a test for the malignancy.

A non-invasive vaginal swab test with high negative predictive value and high sensitivity could potentially be used to rule out cancer in symptomatic women, reducing the need for more invasive procedures.

This peer-reviewed publication provides clear evidence that endometrial cancer signals can be detected from a vaginal swab. It represents a scientific breakthrough and a critical step toward a diagnostic pathway designed around women — not procedures.

Bonnie Anderson, co-founder, chair, and chief executive officer of PinkDx

Clinical Context and Patient Impact

Endometrial cancer is identified as the most common gynecologic malignancy in the United States. We see also noted as one of the few cancers with rising mortality rates.

According to estimates from the American Cancer Society for 2026, there are more than 69,000 new cases and over 14,000 deaths expected in the U.S.

Currently, tens of thousands of women undergo invasive diagnostic procedures annually following symptoms such as postmenopausal bleeding or abnormal bleeding. However, the data indicates that fewer than one in ten of these women will ultimately be diagnosed with cancer.

The current diagnostic journey is described as inefficient for clinicians and patients, often proving to be anxiety-provoking, time-consuming, and painful.

Scientific Significance

The publication of this evidence in the International Journal of Gynecological Cancer challenges existing assumptions regarding how endometrial cancer must be evaluated. By demonstrating that molecular signals are detectable without direct uterine sampling, the research lays a scientific foundation for a patient-centered diagnostic approach.

The development of this method utilizes whole-transcriptome sequencing and machine learning to identify the specific molecular signals necessary for detection.

The breakthrough has received national attention, including coverage on Good Morning America, highlighting the potential for the test to transform the current standard of care for endometrial cancer diagnosis.